Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a well‐established risk factor for cardiovascular disease (CVD). New therapeutic approaches have been developed recently based on the incretin phenomenon, such as the degradation‐resistant incretin mimetic exenatide and the glucagon‐like peptide‐1 (GLP‐1) analogue liraglutide, as well as the dipeptidyl dipeptidase (DPP)‐4 inhibitors, such as sitagliptin, vildagliptin, saxagliptin, which increase the circulating bioactive GLP‐1. GLP‐1 exerts its glucose‐regulatory action via stimulation of insulin secretion and glucagon suppression by a glucose‐dependent way, as well as by weight loss via inhibition of gastric emptying and reduction of appetite and food intake. These actions are mediated through GLP‐1 receptors (GLP‐1Rs), although GLP‐1R‐independent pathways have been reported. Except for the pancreatic islets, GLP‐1Rs are also present in several other tissues including central and peripheral nervous systems, gastrointestinal tract, heart and vasculature, suggesting a pleiotropic activity of GLP‐1. Indeed, accumulating data from both animal and human studies suggest a beneficial effect of GLP‐1 and its metabolites on myocardium, endothelium and vasculature, as well as potential anti‐inflammatory and antiatherogenic actions. Growing lines of evidence have also confirmed these actions for exenatide and to a lesser extent for liraglutide and DPP‐4 inhibitors compared with placebo or standard diabetes therapies. This suggests a potential cardioprotective effect beyond glucose control and weight loss. Whether these agents actually decrease CVD outcomes remains to be confirmed by large randomized placebo‐controlled trials. This review discusses the role of GLP‐1 on the cardiovascular system and addresses the impact of GLP‐1‐based therapies on CVD outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Close Relation of Endothelial Function in the Human Coronary and Peripheral Circulations
Anderson, T. J., Uehata, A., Gerhard, M. D., Meredith, I. T., Knab, S., Delagrange, D., Lieberman, E. H., Ganz, P., Creager, M. A., Yeung, A. C., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00327-4 · Cited by 2,033 · cited 1×
“FMD highly correlates with endothelial dysfunction in the coronary circulation [82] and is also considered to be NO mediated [83].”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Three placebo-controlled studies tried to evaluate the impact of exenatide on lipid parameters [total cholesterol (TC), lowdensity lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)] in patients on metformin alone [115], sulphonylurea alone [116] or metformin plus sulp…”
BackgroundInfluence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000094221.86888.ae · Cited by 1,391
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect seems to be significantly impaired in T2DM due to a reduced secretion of these hormones, accelerated metabolism or defective responsiveness to their action [4].”
Background
Cited by
Cardiac autonomic neuropathy in patients with diabetes mellitus
Dimitropoulos, G. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.17 · Cited by 357
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S.-I. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.016 · Cited by 156
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
Metadata
- Authors
- Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-02-23
- Volume
- 13
- Issue
- 4
- Pages
- 302-312
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2051279660
- Cited by
- 141
- References
- 39
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01345.x
- The paper
- Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011). Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01345.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.